Among the possible signaling pathways, which would be more affected by the aberrant expression of a mesenchymal receptor in an epithelial cell context, the transient vs sustained activations of ERK1/2 or Akt could be good candidates, since they appear to be involved in the FGFR-mediated control of proliferation, survival, differentiation and migration [41] and they represent the target for new anti-cancer therapies [42]. The gene discussed is MAPK3; the disease is cancer.